SCHEMBL20107545

SCHEMBL20107545

COc1ccc([C@@H]2CC2C(=O)n2c(=O)oc3ncccc32)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.45
PDE4B Q07343 5/20 0.40
PDE4A P27815 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TRPM5 Q9NZQ8 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607276 1.00 APP (0.45) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL12723348 0.85 TRPM5 (0.34) PDE4APDE4DNPC1MAPTRAB9A
SCHEMBL21024673 0.82 DEGS1 (0.37) PDE4BPDE4APDE4CPDE4DNPC1
SCHEMBL21025286 0.76 APP (0.48) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL9607146 0.76 APP (0.48) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL13556342 0.72 APP (0.41) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL9607281 0.72 APP (0.46) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL9607147 0.71 APP (0.47) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL9607280 0.71 APP (0.49) APPPDE4BPDE4APDE4CPDE4D
SCHEMBL12723382 0.69 HSD11B1 (0.43) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10786510-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2020-09-29 US disclosed
US-20180117049-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OCCURX PTY LTD (AU) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117049-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION VCAM1, PTGIS, NFKBIA APP 3849/4885PDE4B 2154/4885PDE4A 1543/4885
US-10786510-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation VCAM1, PTGIS, NFKBIA APP 3849/4885PDE4B 2154/4885PDE4A 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.